Skip to main content
. 2021 Aug 4;8:675191. doi: 10.3389/fmed.2021.675191

Figure 1.

Figure 1

Box plot showing plasma concentrations of biomarkers of coagulopathy in non-COVID-19 and COVID-19 patients (Lymphonie study 2018–2020). Plasma concentration of biomarkers of coagulation and/or endothelium and platelet activation was measured within 48 hours of hospitalization in 36 non-COVID-19 and 27 COVID-19 patients with severe pneumonia. COVID-19 patients had significantly higher plasma concentrations of sVCAM1 (D), lower plasma concentration of D-dimers, vWF-A2, sICAM1, sTREM1, VEGF, sP-selectin (A,B,E,F,I,K) and a non-significant difference for plasma levels of sTM, TFPI, uPA, CXCL4, PDGF-AA and PDGF-AB/BB. For each cytokine, P-values from Student t test and Q-value of the false discovery rate (FDR) are indicated. COVID-19, coronavirus disease 2019; CXCL4, platelet C-X-C motif chemokine ligand 4; FDR, false discovery rate; PDGF, platelet derived growth factor; sICAM-1, soluble intercellular adhesion molecule 1; sTREM-1, soluble triggering receptor expressed on myeloid cells 1; sVCAM-1, soluble vascular cell adhesion molecule 1; sTM, soluble thrombomodulin; TFPI, tissue factor pathway inhibitor; uPA, u-plasminogen activator; VEGF, vascular endothelial growth factor; vWF-A2, von Willebrand factor A2 (LYMPHONIE study, 2018–2020).